RE-BVS – Piemonte Repository

Sfoglia per AUTORE
BERDEJA J
Collezione AOU Città della Salute di Torino

Items : 4

Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. in Nature genetics / Nat Genet. 2024 Sep;56(9):1878-1889. doi: 10.1038/s41588-024-01853-0. Epub 2024 Aug 19.

2024
AOU Città della Salute di Torino

Craig D; Rogers J; DeRome M; Toone M; McBride K; Zaugg B; Donnelly A; Kidd P; Stumph J; Collison K; Gamella M; D'Agostino M; Kirchhoff M; Rohrer DC; Livermore B; Blanski A; Tassone E; Stephenson K; Reiman R; McDonald J; Kyman S; Helland A; Boateng M; Cuyugan L; Adkins JR; Yellapantula V; Washington M; Kurdoglu A; Turner B; et alii...

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. in The Lancet. Haematology / Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9.

2022
AOU Città della Salute di Torino

Dimopoulos MA; Richardson PG; Bahlis NJ; Grosicki S; Cavo M; Beksaç M; Legie? W; Liberati AM; Goldschmidt H; Belch A; Magen H; Larocca A; Laubach JP; Petrucci MT; Reece D; White D; Mateos MV; Špi?ka I; Lazaroiu M; Berdeja J; Kaufman JL; Jou YM; Ganetsky A; Popa McKiver M; Lonial S; Weisel K;

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. in Annals of hematology / Ann Hematol. 2021 Sep;100(9):2325-2337. doi: 10.1007/s00277-021-04534-8. Epub 2021 May 10.

2021
AOU Città della Salute di Torino

Zonder J; Boccadoro M; Thompson M; Weisel K; Berdeja J; Lee HC; Leleu X; Huang H; Stull DM; Cherepanov D; Terpos E; Hajek R; Romanus D; Palumbo A; Abonour R; Usmani S; Morgan G; Costello C; Rifkin R; Davies F; Cook G; Puig N; Vela-Ojeda J; Farrelly E; Raju A; Blazer M; Chari A;

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. in The Lancet. Oncology / Lancet Oncol. 2021 Mar;22(3):e105-e118. doi: 10.1016/S1470-2045(20)30756-7.

2021
AOU Città della Salute di Torino

Moreau P; Kumar SK; San Miguel J; Davies F; Zamagni E; Bahlis N; Ludwig H; Mikhael J; Terpos E; Schjesvold F; Martin T; Yong K; Durie BGM; Facon T; Jurczyszyn A; Sidana S; Raje N; van de Donk N; Lonial S; Cavo M; Kristinsson SY; Lentzsch S; Hajek R; Anderson KC; João C; Einsele H; Sonneveld P; Engelhardt M; Fonseca R; et alii...